Clinical trials: Anti-PD-1
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes.
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
- Trial name
- NCT06295159
- Testing
- Nivolumab, Nivolumab + Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hodgkin Lymphoma, Coexisting Medical Conditions
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma
This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses.
- Trial name
- NCT03580408
- Testing
- Nivolumab, Vinblastin
- Where
- 51 sites in Belgium, France
- Volunteers
- 64 people
- Sponsor
- The Lymphoma Academic Research Organisation
Non-muscle Invasive Bladder Cancer
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer.
- Trial name
- CREST (NCT04165317)
- Testing
- PF-06801591, Bacillus Calmette-Guerin
- Where
- 196 sites in United States, Australia and 12 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Malignancies
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in…
- Trial name
- NCT03005782
- Testing
- REGN3767, cemiplimab
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 333 people
- Sponsor
- Regeneron Pharmaceuticals
Gastric Cancer
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
This trial is a multi-center, open, single-arm, superior phase II clinical study.
- Trial name
- NCT05113459
- Testing
- Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guoxin Li
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Esophageal Squamous Cell Carcinoma
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210 combined with nimotuzumab as second-line therapy in patients with advanced cancerous esophageal squamous cell carcinoma.
- Trial name
- NCT03766178
- Testing
- Nimotuzumab + SHR-1210
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Thyroid Cancer, Salivary Gland Cancer
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Phase II, 2-cohort, single arm trial treated with the combination of the following two agents: 1. Pembrolizumab (MK3475) 200mg, every three weeks, iv 2. Docetaxel 75mg/m2, every three weeks, iv
- Trial name
- iPRIME (NCT03360890)
- Testing
- Pembrolizumab, Docetaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Thyroid Cancer
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
This study is a single-arm intervention study. Locally advanced differentiated thyroid carcinoma patients receive neoadjuvant therapy with Donafenib and PD-1 antibody Sintilimab and those who can undergo surgery after neoadjuvant…
- Trial name
- NCT06787911
- Testing
- Donafeib with Sintilimab
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Yu Wang
Solid Tumors
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
This is an entry-into-human study and will assess the effects of eciskafusp alfa (RO7284755) as a single agent and in combination with atezolizumab in adult participants with solid tumors considered responsive to checkpoint…
- Trial name
- NCT04303858
- Testing
- Eciskafusp Alfa, Atezolizumab
- Where
- 12 sites in Belgium, Denmark and 3 more
- Volunteers
- 189 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Squamous Cell Carcinoma
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Epstein-Barr virus (EBV) infections is known to be a high-risk factor to induce nasopharyngeal cancers. To date, EBV-related head and neck squamous cell carcinoma (HNSCC) is still a major concern in east Asia, especially in…
- Trial name
- NCT04139057
- Testing
- EBV-specific TCR-T cell with anti-PD1 auto-secreted element
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xinqiao Hospital of Chongqing
Metastatic Breast Cancer
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Panacea is a phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2- positive metastatic breast cancers
- Trial name
- PANACEA (NCT02129556)
- Testing
- MK-3475
- Where
- 11 sites in Australia, Austria and 3 more
- Volunteers
- 58 people
- Sponsor
- ETOP IBCSG Partners Foundation
Chemotherapy, Anti-pd-1 Antibody
Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas
Recurrent or advanced cervical neuroendocrine carcinoma (NEC) is refractory to multimodal treatment, even to extensive therapy. Chemotherapy, consisting of platinum and etoposide, remains the main therapy for recurrent or…
- Conditions
- Chemotherapy, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma, Adverse Drug Event
- Trial name
- NCT04635956
- Testing
- Drug therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Peripheral T-cell Lymphoma
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of AK104，an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell lymphoma.
- Trial name
- NCT04444141
- Testing
- AK104
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Akeso
Cancer
PULSAR Radiotherapy Plus Anti-PD-1 Therapy in Metastatic Abdominopelvic Tumors
This study evaluates hypofractionated radiotherapy combined with PD-1 inhibitor-based systemic therapy in patients with metastatic solid tumors.
- Trial name
- NCT07383857
- Testing
- pulsed radiotherapy
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Zhen Zhang
Early Melanoma, Advanced Melanoma
Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients
This is a retrospective observational cohort study, the primary objective is investigate the activity and efficacy of anti PD-1 antibodies in children, adolescents and young adult melanoma patients, with radically resected or…
- Trial name
- MELCAYA (NCT06281912)
- Where
- 13 sites in France, Germany and 5 more
- Volunteers
- 70 people
- Sponsor
- Azienda Ospedaliera di Perugia
Gastric Cancer, Hepatocellular Carcinoma
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma or gastric cancer.
- Trial name
- NCT02942329
- Testing
- apatinib, SHR-1210
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Hepatocellular Carcinoma
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Lenvatinib is an oral multi-target receptor tyrosine kinase inhibitor (TKI) inhibitor that mainly inhibits the Endothelial growth factor receptor (VEGFR) VEGFR-1,2,3; Fibroblast growth factor receptor, FGFR) FGFR-1,2,3,4…
- Trial name
- NCT05803928
- Testing
- lenvatinib + anti-PD-1 antibodies, ablation
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hua Li
Advanced Cancer
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
The purpose of this study is to determine whether lirilumab in combination with nivolumab or in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or metastatic solid tumors
- Trial name
- NCT03203876
- Testing
- Lirilumab, Nivolumab, Ipilimumab
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3…
- Trial name
- NCT03406949
- Testing
- obrindatamab, retifanlimab
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- MacroGenics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.